Kamada将停止III期InnovAATe试验，因为预先指定的中期无效性分析显示吸入AAT治疗Alpha-1抗胰蛋白酶缺乏症的试验不太可能在其主要终点方面证明具有统计学意义

2025-12-08 20:06

Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint
Kamada Continues to Supply GLASSIA, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDA
Kamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million
Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026
Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term Growth